CHROMOLOGIC LLC — Department of Defense SBIR Phase I: CBD212-004
CHROMOLOGIC LLC — SBIR Phase I award from Department of Defense.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Defense in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $167,470. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code CBD212-004 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $167,470
- Agency
- Department of Defense · Office for Chemical and Biological Defense
- Program / Phase
- SBIR · Phase I
- Topic
- CBD212-004
- Solicitation
- 21.2
- NAICS
- —
- Place of performance
- CA
- Period
- 2022-02-14 → 2022-08-13
Description
To meet CBD’s need for a multi-dose formulation of scopolamine hydrobromide trihydrite ChromoLogic proposes to develop a vial add-on containing a self-decontamination cap with a self-healing material to eliminate evaporation and contamination risks through needle punctures in the septum. CL will also perform forced degradation and stability tests with a panel of preservatives to select optimal preservative/concentration and achieve target shelf-life. Overall, CL plans to work with the CBD to ensure this product is an amendment to their already existing FDA process for approval of their single-dose formulation.